Telix Pharmaceuticals aligns with FDA on Phase 3 trial

• Telix Pharmaceuticals concluded a Type B meeting with the US FDA regarding its global clinical trial protocol.
• The company's shares experienced upward trading momentum following the regulatory alignment.
• The agreement enables the company to progress recruitment into the next stage of its international prostate cancer study.

Telix Pharmaceuticals (ASX:TLX) aligned with the US regulator to advance its Phase 3 trial after a 36-patient safety study.

The regulatory clearance allows the company to expand its international prostate cancer clinical trial into the United States market.

“This outcome enables submission of our IND amendment,” said Telix Pharmaceuticals Group Chief Medical Officer David N. Cade.

The company stated that the trial continues to recruit patients across five international jurisdictions outside the United States.

Following the announcement, the Telix Pharmaceuticals share price was up at $17.53.

The oncology firm specialises in developing targeted radiopharmaceutical products designed to diagnose and treat various forms of cancer.

The regulatory milestone follows recent late-stage pipeline advancements and international expansion efforts.